Document ID: chunk:federal_register_of_legislation:F2023L01664:clause:1_73307
Version: federal_register_of_legislation:F2023L01664
Segment Type: clause
Provision Reference: sch 1 cl 73307
Character Range: 2027–2719

73307  A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is:                                                   3,000.00
         (a)    to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and
         (b)    including a service described in item 73301
       Applicable once per primary tumour diagnosis